NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Price, News & Analysis $1.72 +0.03 (+1.47%) As of 10:46 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Autolus Therapeutics Stock (NASDAQ:AUTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Autolus Therapeutics alerts:Sign Up Key Stats Today's Range$1.67▼$1.7450-Day Range$1.21▼$1.8052-Week Range$1.18▼$2.70Volume465,215 shsAverage Volume1.75 million shsMarket Capitalization$459.09 millionP/E RatioN/ADividend YieldN/APrice Target$8.75Consensus RatingModerate Buy Company Overview Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications. The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma. Additional clinical and preclinical programs address targets such as BCMA in multiple myeloma and solid tumor antigens, as well as novel constructs aimed at improving T cell persistence and tumor microenvironment penetration. Autolus collaborates with academic institutions and research partners to advance its pipeline and validate emerging technologies. Founded in 2014 as a spin-out from University College London, Autolus is headquartered in London, U.K., with operational sites in the United States and Europe to support clinical trials and manufacturing scale-up. The company is led by Chief Executive Officer Christian Itin, whose background in cell therapy and immuno-oncology guides a leadership team of experienced industry executives and scientific experts. Autolus is committed to expanding global access to its therapies through regulatory filings and strategic partnerships in key markets.AI Generated. May Contain Errors. Read More Autolus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreAUTL MarketRank™: Autolus Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 191st out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAutolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAutolus Therapeutics has a consensus price target of $8.75, representing about 414.7% upside from its current price of $1.70.Amount of Analyst CoverageAutolus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Autolus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Autolus Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.62% of the float of Autolus Therapeutics has been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 10.52, which indicates bearish sentiment.Change versus previous monthShort interest in Autolus Therapeutics has recently decreased by 7.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News SentimentN/A News SentimentAutolus Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Autolus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 20 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.MarketBeat Follows5 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Autolus Therapeutics' insider trading history. Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AUTL Stock News HeadlinesAutolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026May 21, 2026 | globenewswire.comAutolus (AUTL) Q1 2026 Earnings TranscriptMay 18, 2026 | finance.yahoo.comThe SpaceX filing is public. The window is closing.SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the largest in history. The 21-bank syndicate has already locked up shares, so retail investors won't get access. But the S-1 exposed one publicly traded company Musk cannot operate without - and it's still cheap. Dylan Jovine is releasing the ticker free before June 12 changes the price.May 26 at 1:00 AM | Behind the Markets (Ad)Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Rating of "Moderate Buy" from BrokeragesMay 18, 2026 | americanbankingnews.comAutolus Therapeutics Plc Sponsored ADRMay 15, 2026 | edition.cnn.comAutolus Therapeutics PLC (AUTL) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...May 15, 2026 | finance.yahoo.comAutolus Therapeutics (NASDAQ:AUTL) Given New $10.00 Price Target at HC WainwrightMay 15, 2026 | americanbankingnews.comAutolus Therapeutics plc (AUTL) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comSee More Headlines AUTL Stock Analysis - Frequently Asked Questions How have AUTL shares performed this year? Autolus Therapeutics' stock was trading at $1.99 on January 1st, 2026. Since then, AUTL shares have decreased by 14.6% and is now trading at $1.70. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) issued its quarterly earnings data on Friday, May, 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. The business earned $26.22 million during the quarter, compared to the consensus estimate of $26.27 million. Autolus Therapeutics had a negative trailing twelve-month return on equity of 128.59% and a negative net margin of 311.98%. Read the conference call transcript. When did Autolus Therapeutics IPO? Autolus Therapeutics (AUTL) raised $141 million in an IPO on Friday, June 22nd 2018. The company issued 8,823,530 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Autolus Therapeutics' top institutional shareholders include Renaissance Technologies LLC (0.86%), Bank of America Corp DE (0.69%), Cetera Investment Advisers (0.42%) and Aubrey Capital Management Ltd (0.05%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and Company Calendar Last Earnings5/15/2026Today5/26/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 7 days, AUTL's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUTL CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees330Year Founded2014Price Target and Rating Average Price Target for Autolus Therapeutics$8.75 High Price Target$10.00 Low Price Target$5.00 Potential Upside/Downside+407.2%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$287.53 million Net Margins-311.98% Pretax Margin-311.32% Return on Equity-128.59% Return on Assets-46.25% Debt Debt-to-Equity RatioN/A Current Ratio5.80 Quick Ratio5.28 Sales & Book Value Annual Sales$75.39 million Price / Sales6.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book4.21Miscellaneous Outstanding Shares266,140,000Free Float197,744,000Market Cap$459.09 million OptionableOptionable Beta1.93 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:AUTL) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredNew Warning From Our CEOMarketWise CEO Dr. David 'Doc' Eifrig, a former Goldman Sachs derivatives trader, has released an urgent brief...Stansberry Research | SponsoredI was right about SpaceX. Now here's the part that mattersGoldman Sachs and JP Morgan have already been tied to allocations surrounding the SpaceX deal. When the bigges...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
